Phreesia (NYSE:PHR) Announces Earnings Results

Phreesia (NYSE:PHR) released its earnings results on Wednesday. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03, FiscalAI reports. Phreesia had a net margin of 0.48% and a return on equity of 3.23%. The firm had revenue of $130.94 million during the quarter, compared to analyst estimates of $130.08 million.

Phreesia Trading Up 2.2%

Shares of NYSE PHR traded up $0.20 during midday trading on Wednesday, reaching $9.15. 1,878,778 shares of the stock were exchanged, compared to its average volume of 1,799,773. The business has a 50-day simple moving average of $9.57 and a two-hundred day simple moving average of $13.78. The company has a market capitalization of $565.05 million, a price-to-earnings ratio of 304.90 and a beta of 0.89. Phreesia has a 12 month low of $7.77 and a 12 month high of $32.76. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.53 and a quick ratio of 1.53.

More Phreesia News

Here are the key news stories impacting Phreesia this week:

• Negative Sentiment: A shareholder class action lawsuit has been filed alleging Phreesia made false and misleading statements or omitted material facts about its growth prospects, especially around slowing growth in Network Solutions. Article Title
• Negative Sentiment: Multiple law firms issued reminders and recruitment notices for the July 13, 2026 lead-plaintiff deadline, keeping the lawsuit in focus and increasing overhang on the shares. Article Title
• Negative Sentiment: Levi & Korsinsky said Phreesia’s March 30 corrective disclosure allegedly revealed concealed weakness in pharmaceutical marketing, which it claims wiped out about $3.03 per share in value. Article Title
• Neutral Sentiment: Several firms, including Rosen, Pomerantz, Howard G. Smith, Frank R. Cruz, Faruqi & Faruqi, and others, reiterated that a class action is already underway and that investors may seek to be lead plaintiffs by the deadline. Article Title

Insider Activity at Phreesia

In related news, General Counsel Allison C. Hoffman sold 6,176 shares of the business’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $9.06, for a total value of $55,954.56. Following the sale, the general counsel directly owned 157,309 shares of the company’s stock, valued at approximately $1,425,219.54. The trade was a 3.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Balaji Gandhi sold 3,829 shares of the business’s stock in a transaction on Wednesday, March 25th. The shares were sold at an average price of $11.26, for a total transaction of $43,114.54. Following the completion of the sale, the chief financial officer directly owned 146,740 shares in the company, valued at $1,652,292.40. This represents a 2.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 50,493 shares of company stock valued at $461,983. 5.20% of the stock is owned by insiders.

Institutional Investors Weigh In On Phreesia

Institutional investors have recently added to or reduced their stakes in the stock. Quadrature Capital Ltd bought a new stake in Phreesia in the 4th quarter valued at $447,000. Campbell & CO Investment Adviser LLC bought a new stake in Phreesia in the 4th quarter valued at $433,000. Raymond James Financial Inc. lifted its position in Phreesia by 2.7% during the 2nd quarter. Raymond James Financial Inc. now owns 14,049 shares of the company’s stock worth $400,000 after buying an additional 375 shares in the last quarter. PharVision Advisers LLC bought a new stake in Phreesia during the 3rd quarter worth about $345,000. Finally, Polymer Capital Management US LLC bought a new stake in Phreesia during the 4th quarter worth about $335,000. 92.10% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have commented on the stock. BMO Capital Markets lowered their target price on shares of Phreesia from $32.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, March 31st. KeyCorp lowered their target price on shares of Phreesia from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Monday, April 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a report on Wednesday, January 28th. Wells Fargo & Company reissued an “equal weight” rating and set a $9.00 price target (down from $15.00) on shares of Phreesia in a research report on Wednesday, May 20th. Finally, Mizuho reduced their price target on shares of Phreesia from $22.00 to $19.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 24th. Ten investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $19.06.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.